Oncternal Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q2 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Oncternal Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q2 2010 to Q3 2024.
  • Oncternal Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$8.46M, a 14.2% increase year-over-year.
  • Oncternal Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$34.6M, a 17.1% increase year-over-year.
  • Oncternal Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$39.5M, a 10.6% increase from 2022.
  • Oncternal Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$44.2M, a 41% decline from 2021.
  • Oncternal Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$31.3M, a 81.9% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$34.6M -$8.46M +$1.4M +14.2% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-06
Q2 2024 -$36M -$8.56M +$407K +4.54% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 -$36.4M -$8.39M +$3.1M +27% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 -$39.5M -$9.16M +$2.24M +19.6% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-07
Q3 2023 -$41.7M -$9.86M +$1.26M +11.4% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-06
Q2 2023 -$43M -$8.97M +$2.78M +23.6% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 -$45.8M -$11.5M -$1.58M -16% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 -$44.2M -$11.4M -$3.33M -41.2% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-07
Q3 2022 -$40.8M -$11.1M -$1.5M -15.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$39.3M -$11.7M -$4.06M -52.8% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 -$35.3M -$9.9M -$3.96M -66.5% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 -$31.3M -$8.07M -$5.52M -216% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-09
Q3 2021 -$25.8M -$9.63M -$5.24M -119% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$20.6M -$7.68M -$2.15M -38.8% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 -$18.4M -$5.95M -$1.21M -25.5% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 -$17.2M -$2.56M +$1.6M +38.5% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-10
Q3 2020 -$18.8M -$4.4M +$497K +10.2% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 -$19.3M -$5.54M +$17.3M +75.8% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 -$36.6M -$4.74M -$2.44M -107% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 -$34.2M -$4.16M +$1.26M +23.3% Oct 1, 2019 Dec 31, 2019 10-K/A 2021-03-12
Q3 2019 -$35.4M -$4.89M -$2.99M -158% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-04
Q2 2019 -$32.5M -$22.8M -$20.4M -847% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 -$12M -$2.29M -$803K -53.9% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 -$11.2M -$5.42M +$3.86M +41.6% Oct 1, 2018 Dec 31, 2018 10-K 2019-03-18
Q3 2018 -$15.1M -$1.9M +$6.61M +77.7% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-08
Q2 2018 -$21.7M -$2.41M +$3.99M +62.3% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-09
Q1 2018 -$25.7M -$1.49M +$4.76M +76.2% Jan 1, 2018 Mar 31, 2018 10-Q 2019-08-09
Q4 2017 -$30.4M -$9.28M -$2.41M -35.2% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-18
Q3 2017 -$28M -$8.5M -$1.59M -23% Jul 1, 2017 Sep 30, 2017 10-K 2019-03-18
Q2 2017 -$26.4M -$6.41M -$353K -5.83% Apr 1, 2017 Jun 30, 2017 10-K 2019-03-18
Q1 2017 -$26.1M -$6.25M -$8.36M -397% Jan 1, 2017 Mar 31, 2017 10-K 2019-03-18
Q4 2016 -$17.7M -$6.86M -$3.63M -112% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-13
Q3 2016 -$14.1M -$6.91M -$41.8M -120% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-13
Q2 2016 $27.7M -$6.05M +$41.9M +87.4% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-13
Q1 2016 -$14.2M $2.11M +$4.49M Jan 1, 2016 Mar 31, 2016 10-K 2018-03-13
Q4 2015 -$18.7M -$3.23M +$11.3M +77.8% Oct 1, 2015 Dec 31, 2015 10-K 2017-03-24
Q3 2015 -$30M $34.9M +$39.8M Jul 1, 2015 Sep 30, 2015 10-K 2017-03-24
Q2 2015 -$69.8M -$48M -$37M -338% Apr 1, 2015 Jun 30, 2015 10-K 2017-03-24
Q1 2015 -$32.8M -$2.38M +$6.6M +73.5% Jan 1, 2015 Mar 31, 2015 10-K 2017-03-24
Q4 2014 -$39.4M -$14.5M -$6.76M -86.7% Oct 1, 2014 Dec 31, 2014 10-K 2016-03-15
Q3 2014 -$32.7M -$4.94M +$4M +44.8% Jul 1, 2014 Sep 30, 2014 10-K 2016-03-15
Q2 2014 -$36.7M -$10.9M +$1.86M +14.5% Apr 1, 2014 Jun 30, 2014 10-K 2016-03-15
Q1 2014 -$38.5M -$8.99M +$3.6M +28.6% Jan 1, 2014 Mar 31, 2014 10-K 2016-03-15
Q4 2013 -$42.1M -$7.79M +$2.93M +27.3% Oct 1, 2013 Dec 31, 2013 10-K 2016-03-15
Q3 2013 -$45M -$8.94M -$14M -275% Jul 1, 2013 Sep 30, 2013 10-Q 2014-11-10
Q2 2013 -$31M -$12.8M -$2.42M -23.3% Apr 1, 2013 Jun 30, 2013 10-Q 2014-08-05
Q1 2013 -$28.6M -$12.6M -$1.5M -13.6% Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-12
Q4 2012 -$27.1M -$10.7M -$33K -0.31% Oct 1, 2012 Dec 31, 2012 10-K 2014-03-12
Q3 2012 -$27M $5.1M +$14.4M Jul 1, 2012 Sep 30, 2012 10-K 2014-03-12
Q2 2012 -$41.5M -$10.4M +$292K +2.74% Apr 1, 2012 Jun 30, 2012 10-K 2014-03-12
Q1 2012 -$41.8M -$11.1M -$8.49M -327% Jan 1, 2012 Mar 31, 2012 10-K 2014-03-12
Q4 2011 -$33.3M -$10.7M Oct 1, 2011 Dec 31, 2011 10-K 2013-03-05
Q3 2011 -$9.34M -$769K -8.97% Jul 1, 2011 Sep 30, 2011 10-K 2013-03-05
Q2 2011 -$10.7M +$2.27M +17.5% Apr 1, 2011 Jun 30, 2011 10-K 2013-03-05
Q1 2011 -$2.6M Jan 1, 2011 Mar 31, 2011 10-K 2013-03-05
Q3 2010 -$8.58M Jul 1, 2010 Sep 30, 2010 10-Q 2011-11-04
Q2 2010 -$12.9M Apr 1, 2010 Jun 30, 2010 10-Q 2011-08-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.